Ozi ndị ọzọ ― Igbo

Urticaria na-enyekarị welts ewelitere na-egbu mgbu. Mgbe ụfọdụ a na-esonyere ya na ọzịza nke anụ ahụ dị n'okpuru. Ọgwụgwọ bụ isi gụnyere ịzere ihe na-akpalite, ma ọ bụrụ na amaara ya. Ọgwụ nke mbụ na-agụnye antihistamines ọhụrụ, nke enwere ike ịhazi ya na doses dị elu ma ọ bụrụ na ọ dị mkpa. Enwere ike ịgbakwunye ọgwụ ndị ọzọ dị ka antihistamines ochie, ndị na-egbochi H2, ndị na-anabata ndị na-anabata leukotriene, ọgwụ mgbochi siri ike, na obere usoro nke corticosteroids dị ka nkwado ọzọ. N'ọnọdụ ebe urticaria na-aga n'ihu n'agbanyeghị usoro ndị a, enwere ike iziga ndị ọrịa na ndị ọkachamara maka ọgwụgwọ ndị ọzọ dị ka omalizumab ma ọ bụ cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Nyocha a na-akọwapụta ụkpụrụ nduzi kachasị ọhụrụ maka ọgwụgwọ urticaria ma na-enye nghọta ọhụrụ nke ihe kpatara ya.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids